AGI Therapeutics scraps Rezular after trial failure

15th May 2009 07:34

AGI Therapeutics is to scrap further development its irritable bowel syndrome treatment Rezular after a phase 3 trial indicated no real benefits.AGI said the trial showed no statistically significant differences between treatments in the primary endpoint of patient reported adequate relief of IBS symptoms. There were also no statistically significant differences between treatments in adequate relief of pain/discomfort or change in severity of IBS pain. Rezular did score well in a number of secondary endpoints, AGI added."We are very disappointed that this study did not achieve its primary clinical endpoint. While we saw evidence that Rezular has activity in many aspects of this multi-symptom disease, as in our earlier study, our experience in bringing products to market suggests to us that the pursuit of this product as a therapy for IBS-D would not be a prudent use of our resources," chief executive John Devane said.AGI will now focus on its AGI004 treatment of chemotherapy-induced diarrhoea (CID) in cancer patients.